RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

It's not the case that all Ampa-modulating/Ampakine programs demised after the CX-717 histopath issues.In fact there has been a brief revival of AMPA-interest: Takeda, Pfizer, and Servier all ran trials in the past eighteen months (Servier is still using CX1632)--it can be safely assumed that all of them did thorough animal testing before going into human testing, and did not find tox problems.
However--all failed in PhII, Servier most recently. It is possible that, separate from the histopath issue, that companies all err on the low side of dosing because of the longheld (and not unjustified) worry about seizure-induction,and thus miss out on efficacy, but that is speculative.

The CX-1739 tox issue will likely clear up (if chronic dosing didnt cause a repetition of the issue, why would brief dosing?). But the task of finding a partner would have been infinitely easier had any of these other programs been successful.

NeuroPespective